Histidine-rich glycoprotein as an early biomarker of preeclampsia

American Journal of Hypertension

Volumn 24, Issue 4, 2011, Pages 496-501

  Bolin, Marie ^a,b   Åkerud, Peter ^a   Hansson, Agneta ^c,d   Åkerud, Helena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b SUNDSVALL HOSPITAL   (Sweden)

^c Primary Care Research Unit   (Sweden)

^d Department of Obstetrics and Gynecology ^*  (Sweden)

Author keywords

angiogenesis; blood pressure; histidine rich glycoprotein; hypertension; prediction; preeclampsia

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; HISTIDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; LONGITUDINAL STUDY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; LONGITUDINAL STUDIES; PRE-ECLAMPSIA; PREGNANCY; PROSPECTIVE STUDIES; PROTEINS; SWEDEN;

EID: 79952991708     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.264     Document Type: Article

References (33)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365:785-799.
2. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999; 106:1019-1022. (Pubitemid 29457082)
3. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200-1204. (Pubitemid 20007682)
4. Heilmann L, Rath W, Pollow K. Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost 2007; 13:285-291. (Pubitemid 47000565)
5. Wickström K, Edelstam G, Löwbeer CH, Hansson LO, Siegbahn A. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 2004; 64:31-40. (Pubitemid 38283207)
6. Konijnenberg A, Stokkers EW, van der Post JA, Schaap MC, Boer K, Bleker O P, Sturk A. Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol 1997; 176:461-469. (Pubitemid 27107940)
7. Holthe MR, Staff AC, Berge LN, Lyberg T. Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women. Am J Obstet Gynecol 2004; 190:1128-1134. (Pubitemid 38561536)
8. Williams VK, Griffiths AB, Carbone S, Hague WM. Fibrinogen concentration and factor VIII activity in women with preeclampsia. Hypertens Pregnancy 2007; 26:415-421. (Pubitemid 350232900)
9. Manten GT, Sikkema JM, Franx A, Hameeteman TM, Visser GH, de Groot PG, Voorbij HA. Increased high molecular weight fibrinogen in pre-eclampsia. Thromb Res 2003; 111:143-147. (Pubitemid 37532851)
10. Kårehed K, Wikström AK, Olsson AK, Larsson A, Olovsson M, Akerud H. Fibrinogen and histidine-rich glycoprotein in early-onset preeclampsia. Acta Obstet Gynecol Scand 2010; 89:131-139.
11. Olsson AK, Larsson H, Dixelius J, Johansson I, Lee C, Oellig C, Björk I, Claesson-Welsh L. A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization. Cancer Res 2004; 64:599-605. (Pubitemid 38120899)
12. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3:1894-1904. (Pubitemid 41716577)
13. Blank M, Shoenfeld Y. Histidine-rich glycoprotein modulation of immune/ autoimmune, vascular, and coagulation systems. Clin Rev Allergy Immunol 2008; 34:307-312.
14. Bolin M, Wiberg-Itzel E, Wikström AK, Goop M, Larsson A, Olovsson M, Akerud H. Angiopoietin-1/angiopoietin-2 ratio for prediction of preeclampsia. Am J Hypertens 2009; 22:891-895.
15. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic J P, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21:9-23.
16. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs B P, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683. (Pubitemid 38364626)
17. Fayyad AM, Harrington K F. Prediction and prevention of preeclampsia and IUGR. Early Hum Dev 2005; 81:865-876. (Pubitemid 41726207)
18. Steinberg G, Khankin EV, Karumanchi SA. Angiogenic factors and preeclampsia. Thromb Res 2009; 123 Suppl 2:S93-S99.
19. Cnossen JS, ter Riet G, Mol BW, van der Post JA, Leeflang MM, Meads CA, Hyde C, Khan KS. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand 2009; 88:758-765.
20. Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting pre-eclampsia. Mol Aspects Med 2007; 28:227-244. (Pubitemid 46843194)
21. Than NG, Romero R, Hillermann R, Cozzi V, Nie G, Huppertz B. Prediction of preeclampsia - a workshop report. Placenta 2008; 29 Suppl A:S83-S85.
22. Haukkamaa M, Morgan W T, Koskelo P. Serum histidine-rich glycoprotein during pregnancy and hormone treatment. Scand J Clin Lab Invest 1983; 43: 591-595. (Pubitemid 14229092)
23. Halbmayer WM, Hopmeier P, Feichtinger C, Rubi K, Fischer M. Histidine-rich glycoprotein (HRG) in uncomplicated pregnancy and mild and moderate preeclampsia. Thromb Haemost 1992; 67:585-586.
24. Tatra G, Nasr F, Hoyer E. Histidine-rich-3,8S-α 2-glycoprotein in normal pregnancy and EPH-gestosis. Z Geburtshilfe Perinatol 1983, 187:124-126. (Pubitemid 13069541)
25. Dixelius J, Olsson AK, Thulin A, Lee C, Johansson I, Claesson-Welsh L. Minimal active domain and mechanism of action of the angiogenesis inhibitor histidine-rich glycoprotein. Cancer Res 2006; 66:2089-2097.
26. Lee C, Dixelius J, Thulin A, Kawamura H, Claesson-Welsh L, Olsson AK. Signal transduction in endothelial cells by the angiogenesis inhibitor histidine-rich glycoprotein targets focal adhesions. Exp Cell Res 2006; 312:2547-2556. (Pubitemid 44036805)
27. Simantov R, Febbraio M, Crombie R, Asch AS, Nachman RL, Silverstein RL. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J Clin Invest 2001; 107:45-52. (Pubitemid 32047413)
28. Jespersen J, Gram J, Bach E. A sequential study of plasma histidine-rich glycoprotein and plasminogen in patients with acute myocardial infarction and deep vein thrombosis. Thromb Haemost 1984; 51:99-102. (Pubitemid 14159211)
29. Saigo K, Yoshida A, Ryo R, Yamaguchi N, Leung LL. Histidine-rich glycoprotein as a negative acute phase reactant. Am J Hematol 1990; 34:149-150. (Pubitemid 20180108)
30. Jones AL, Hulett MD, Parish CR. Histidine-rich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems. Immunol Cell Biol 2005; 83: 106-118. (Pubitemid 40469318)
31. Leung LL. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986; 77:1305-1311. (Pubitemid 16047154)
32. Leung LL, Harpel PC, Nachman RL, Rabellino EM. Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983; 62:1016-1021. (Pubitemid 14237323)
33. Janes SL, Goodall AH. Flow cytometric detection of circulating activated platelets and platelet hyper-responsiveness in pre-eclampsia and pregnancy. Clin Sci 1994; 86:731-739. (Pubitemid 24181967)